MetaCap

Xeris Biopharma Holdings Inc. (XERS)

NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

16.97+0.35 (+2.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XERS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.03
52-week range
5.25 – 17.28
Day range
16.53 – 17.04
Volume / Avg
2.86M / 2.86M
Beta
—

52-week range

$5.25$17.28

XERS stock today

On Nov 20, XERS ended the session at $16.97, adding $0.35 (2.11%), versus the S&P 500's 3.70% decline. At this level, XERS sits near the top of its 52-week range of $5.25 to $17.28: 1.8% below the high, set on Nov 18, 2026 and 223.2% above the low. XERS is up 116.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 148.5%.

Xeris Biopharma has posted a net loss over the last twelve months (EPS of -$0.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Xeris Biopharma

Company profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. John P. Shannon
Headquarters
Chicago, IL
Employees
435
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Xeris Biopharma generated $291.8 million in revenue, up 43.7% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $554,000, for a net margin of 0.2% versus a median of -85.9% in the prior 5 years. Gross margin was 85.4% (up from 81.9%) and operating margin 8.5%.

Xeris Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$291.85M$203.07M$163.91M$110.25M$49.59M
Growth+43.72%+23.89%+48.68%+122.32%+142.67%
Net income$554.00K$-54.84M$-62.26M$-94.66M$-122.72M
EPS (diluted)$0.00$-0.37$-0.45$-0.70$-1.55

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$17.29+1.89%

  • Strong buy 1
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $21.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.06 vs $0.02
Surprise
+200.00%

XERS news

All XERS news

Xeris Biopharma peers

Health Care sector
XERS peer companies
CompanyPrice% ChgMarket capCompare
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs XERS
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs XERS
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs XERS
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs XERS
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs XERS
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs XERS
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs XERS
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs XERS

Indexes, lists and sector

Xeris Biopharma stock FAQ

What is Xeris Biopharma's stock price today?

XERS last traded at $16.97 as of Nov 20, 4:00 PM EST, up 2.11% on the day. Prices are delayed at least 15 minutes.

Who is Xeris Biopharma's CEO?

Mr. John P. Shannon is the chief executive officer of Xeris Biopharma Holdings Inc., which has about 435 employees.

What is the XERS 52-week high?

The 52-week high for XERS is $17.28 and the 52-week low is $5.25. The stock is currently 1.8% below its high.

Compare XERS